Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2024 | Evaluating patient experiences in a multidisciplinary breast cancer clinic

Stephanie Graff • 16 May 2024
ESMO Breast 2024
Breast Cancer

Stephanie Graff, MD, FACP, FASCO, Brown University, Providence, RI, discusses a prospective study on patient experiences at the Brown Cancer Center’s multidisciplinary breast cancer clinic. The study found that despite long appointment times, patients valued the comprehensive, one-stop approach to care, appreciating the opportunity to see multiple specialists and support team members in a single visit. The positive feedback supports the continuation and improvement of multidisciplinary care. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Stephanie Graff

Ask the Expert: Stephanie Graff answers your breast cancer questions at ESMO 2025
9:52
Ask the Expert: Stephanie Graff answers your breast cancer questions at ESMO 2025
Stephanie Graff • 18 Oct 2025
NATALEE and monarchE: ribociclib and abemaciclib in HR+/HER2- breast cancer
1:48
NATALEE and monarchE: ribociclib and abemaciclib in HR+/HER2- breast cancer
Stephanie Graff • 16 May 2024
Sequencing first-line CDK4/6 inhibitors in metastatic breast cancer
1:07
Sequencing first-line CDK4/6 inhibitors in metastatic breast cancer
Stephanie Graff • 16 May 2024
ELAINE 1: ESR1 mutations in ctDNA from ER+/HER2- mBC treated with lasofoxifene or fulvestrant
2:06
ELAINE 1: ESR1 mutations in ctDNA from ER+/HER2- mBC treated with lasofoxifene or fulvestrant
Stephanie Graff • 7 Dec 2022

Related Videos

CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals